FDA approves AstraZeneca's triple combination therapy for type 2 diabetes

The FDA on Thursday approved a once-daily, extended-release combination of the SGLT2 inhibitor dapagliflozin, the DPP-IV inhibitor saxagliptin and metformin for the treatment of type 2 diabetes, according to a press release from AstraZeneca.